Takeda and hutchmed announce publication of phase 3 fresco-2 results in the lancet

Osaka, japan & cambridge, mass. & hong kong & shanghai & florham park, n.j.--(business wire)--takeda (tse:4502/nyse:tak) and hutchmed (china) limited (nasdaq/aim:hcm, hkex:13) (hutchmed) today announced that results of the phase 3 fresco2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (crc) were published in the lancet. the publication provides details of the fresco-2 study results as of june 24, 2022. summary results from this cut-off date were p.
TAK Ratings Summary
TAK Quant Ranking